India's First Drug EMR Could Set Off Litigation Wave, Industry Warns
Novartis' EMR grant, issued by the Controller General of Patents and Trademarks of India, blocks the duplication and sale of the drug by any other company for five years.
"We are in an uncharted territory and we are evaluating all our options carefully. We hope that the Indian government will ensure the...
To view the full article, register now.